Joseph Tseng, MD
Retina Specialist · New York, NYNPI 1558518332
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Mallinckrodt Enterprises LLC accounts for 60.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $4,111 and has fallen 91.7% since, to $342 in 2025.
Across 60 payments — averaging $103.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$4K
- Mallinckrodt Hospital Products Inc.$548
- Glaukos Corporation$276
- Johnson & Johnson Surgical Vision, Inc.$215
- Alcon$172
- Genentech USA, Inc.$158
- plus $1K from 11 others
What the payments were for
- Consulting fees$3,37554%
- Food & beverage$2,59942%
- Education$2003%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 4 | $3,739 |
| Mallinckrodt Hospital Products Inc. | 14 | $548 |
| Glaukos Corporation | 2 | $276 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $215 |
| Alcon | 3 | $172 |
| Genentech USA, Inc. | 8 | $158 |
| Alimera Sciences, Inc. | 1 | $150 |
| Dompe US, Inc. | 1 | $149 |
| Novartis | 2 | $147 |
| AbbVie(2 entities) | 6 | $143 |
| Eyepoint US, Inc. | 3 | $141 |
| Rxsight Inc | 1 | $98 |
| Astellas Pharma US Inc | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| Bausch & Lomb Americas Inc. | 2 | $52 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$3,860
- Iluvien$150
- Oxervate$149
- iStent inject Trabecular Micro-Bypass Stent System$142
- iDose$134
- XIIDRA$125
- AcrySof$123
- Tecnis IOL$115
- VERITAS Vision System$115
- CATALYS SYSTEM$115
How this compares
$6,193 in reported general payments places this provider in the 70th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 84 | $90,569 |
| EyleaAflibercept | 17 | $41,494 |
| LumiganBimatoprost | 86 | $39,830 |
| XiidraLifitegrast | 38 | $28,602 |
| ProlensaBromfenac Sodium | 26 | $9,050 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $8,358 |
| Prednisolone Acetate | 188 | $7,352 |
| VyzultaLatanoprostene Bunod | 23 | $7,222 |
| RhopressaNetarsudil Mesylate | 12 | $6,702 |
| Brimonidine Tartrate | 126 | $5,559 |
| AlrexLoteprednol Etabonate | 14 | $4,366 |
| Difluprednate | 42 | $3,974 |
| Loteprednol Etabonate | 27 | $3,781 |
| Lotemax SmLoteprednol Etabonate | 13 | $3,459 |
| Timolol Maleate | 43 | $3,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $143 | $138,757201 claims |
| Regeneron Healthcare Solutions, Inc.Eylea | $84 | $41,49417 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $52 | $35,82461 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Alrex, Loteprednol Etabonate, Lotemax Sm | $15 | $20,65580 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 99 retina specialist providers in New York.
Other retina specialist in New York
- Szilard KissNew York$195K
- Donald D'amicoNew York$109K
- Gareth LemaNew York$11K
- Megan Ridley LaneNew York$11K
- Carl WilkinsNew York$9K
- Gennady LandaNew York$7K
- Ben CohenNew York$5K
- Alan SheymanNew York$4K
- Steven AgemyNew York$3K
- Louis AngiolettiNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.